CAR T-cell Therapy

The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

Treatment with P-BCMA-ALLO1 demonstrated clinical activity and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason CAR-T cell therapy fails in some patients.

The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

The FDA has granted fast track designation to the allogeneic CAR T-cell therapy CB-012 for relapsed/refractory acute myeloid leukemia.

The EMA has expanded the indication for lisocabtagene maraleucel to include the treatment of patients with relapsed or refractory follicular lymphoma.

The FDA has granted fast track designation to Deltacel in combination with low-dose radiation for pretreated metastatic non–small cell lung cancer.

The FDA cleared the SeCore CDx HLA A Sequencing System as a companion diagnostic for afamitresgene autoleucel in advanced synovial sarcoma.

Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.

The FDA has granted accelerated approval to afamitresgene autoleucel for select patients with pretreated unresectable or metastatic synovial sarcoma.

The incidence of ICANS and CRS post-CAR T-cell therapy decreased after 2 weeks in patients with DLBCL, supporting a reduction of the monitoring period.

Francisco Hernandez-Ilizaliturri, MD, details factors that influence CAR T-cell therapy selection in relapsed/refractory follicular lymphoma.

GLPG5101 produced high CRs in patients with relapsed/refractory non-Hodgkin lymphoma, indicating the feasibility of decentralized CAR T manufacturing.

Cilta-cel improved overall survival vs standard regimens in relapsed/lenalidomide-refractory multiple myeloma after 1 prior line of therapy.

Armored huCART19-IL18 treatment was tolerable in patients with relapsed/refractory lymphomas who progressed after CD19-directed CAR T-cell therapy.

The FDA has modified the risk evaluation and mitigation strategies for CAR T-cell therapies approved for hematologic malignancies.

Liso-cel continued to show improved disease control and EFS and PFS vs SOC in the second-line treatment of patients with large B-cell lymphoma.

MB-106 showcased a favorable safety profile and elicited responses in heavily pretreated patients with refractory Waldenström macroglobulinemia.

Minoo Battiwalla, MD, discusses the role of bispecific antibodies as an alternative to CAR T-cell therapies in NHL, treatment strategies for aggressive follicular lymphomas, and more.